X
Xiao-Yong Liu
Researcher at Centers for Disease Control and Prevention
Publications - 2
Citations - 1087
Xiao-Yong Liu is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Adverse effect & Vaccination. The author has an hindex of 2, co-authored 2 publications receiving 506 citations.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Biao Kan,Yaling Hu,Haiyan Mao,Qian-Qian Xin,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Xuejie Gong,Chuan Qin,Yuansheng Hu,Xiao-Yong Liu,Guo-Liang Cui,Cong-Bing Jiang,Hengming Zhang,Jingxin Li,Minnan Yang,Xiao-Juan Lian,Yan Song,Jinxing Lu,Xiangxi Wang,Miao Xu,Qiang Gao,Fengcai Zhu +29 more
TL;DR: Favorable safety and immunogenicity of CoronaVac was demonstrated on both schedules and both dosages, which support the conduction of phase 3 trial with optimum schedule/dosage per different scenarios.